Granahan Investment Management, LLC Affimed N.V. Transaction History

Granahan Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $1,586 - $3,532	-1,442 Reduced 0.04%	3,839,548 $4.76 Million
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $119,275 - $202,038	-60,855 Reduced 1.56%	3,840,990 $7.91 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $3.1 Million - $6.63 Million	1,364,917 Added 53.8%	3,901,845 $10.8 Million
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $3.11 Million - $4.76 Million	-842,448 Reduced 24.93%	2,536,928 $11.1 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $14,370 - $18,919	2,676 Added 0.08%	3,379,376 $18.7 Million
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $1.66 Million - $2.25 Million	-299,595 Reduced 8.15%	3,376,700 $20.9 Million
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $2.27 Million - $3.32 Million	291,557 Added 8.61%	3,676,295 $31.2 Million
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $8.06 Million - $13.4 Million	1,574,566 Added 86.98%	3,384,738 $26.8 Million
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $5.72 Million - $12.7 Million	1,810,172 New	1,810,172 $10.5 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $155M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.